|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:ATCCode
|
B03XA06
|
|
gptkbp:brand
|
gptkb:Reblozyl
|
|
gptkbp:CASNumber
|
1133439-90-0
|
|
gptkbp:developer
|
gptkb:Celgene
gptkb:Acceleron_Pharma
|
|
gptkbp:EMA_approval_date
|
2020-06-25
|
|
gptkbp:FDAApproved
|
2019-11-08
|
|
gptkbp:form
|
injection
powder for solution for injection
|
|
gptkbp:genericName
|
gptkb:luspatercept
|
|
gptkbp:hasMolecularFormula
|
C40H65N9O9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Reblozyl
|
|
gptkbp:indication
|
anemia in beta thalassemia
anemia in myelodysplastic syndromes
|
|
gptkbp:isProtein
|
yes
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
erythroid maturation agent
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
headache
hypertension
bone pain
|
|
gptkbp:target
|
gptkb:TGF-beta_superfamily_ligands
|
|
gptkbp:therapeuticArea
|
hematology
|
|
gptkbp:UNII
|
6Y7M7410U1
|
|
gptkbp:bfsParent
|
gptkb:luspatercept
|
|
gptkbp:bfsLayer
|
6
|